This is a free sample of content from Multiple Sclerosis.
Click here for more information on how to buy the book.

Index

A

AHR. *See* Aryl hydrocarbon receptor
AKT, regulatory T cell function, 194–196
Alemtuzumab
  B-cell effects, 334
  clinical trials
    design, 304
    efficacy in multiple sclerosis, 304–306, 310
  guidelines, 307
  overview, 303–304
  prospects for study, 310–311
  safety
    infection, 306–308
    infusion reaction, 306
    long-term immunological effects, 309–310
    pregnancy and lactation, 309
    proliferative disorders, 308
    secondary autoimmunity, 308–309
Antibody microarray, biomarker utility, 231
ApoE, biomarker utility, 229
Aryl hydrocarbon receptor (AHR), astrocyte, 130–131
Astrocyte
  environmental signals, 132–133
  functional overview, 127–129
  multiple sclerosis pathophysiology
    aryl hydrocarbon receptor, 130–131
    overview, 129–130
    prospects for study, 134–135
    sphingolipid metabolism, 132
    tools for study, 133–134
Atacicept, clinical trials, 334–335

B

BBB. *See* Blood–brain barrier
B cell
  alemtuzumab effects, 334
  antibody response in multiple sclerosis, 205–207, 327–328
  antigen presentation and inflammation, 207–208
  cytokine secretion
    granulocyte macrophage colony-stimulating factor, 210
    interleukin 6, 209
interleukin 10, 208
    interleukin 15, 209–210
    interleukin 35, 208
    transforming growth factor β, 208
    tumor necrosis factor, 209
  dimethylfumarate effects, 334
  experimental autoimmune encephalitis role, 81–82
  glatiramer acetate modulation, 266–267, 333–334
  interferon modulation, 333
  meningeal inflammation role, 210–211
  mitoxantrone effects, 334
  natalizumab effects, 334
  therapeutic targeting
    adverse effects, 332–333
    atacicept, 334–335
    CD20 depletion, 328–330
    overview, 203–204
    progressive multiple sclerosis, 330–332
    prospects, 335–336
  tolerance in multiple sclerosis, 204–205
  trafficking in multiple sclerosis, 205
BDNF. *See* Brain-derived neurotrophic factor
Biomarkers. *See also specific biomarkers*
  biobanking, 220–221
  candidate biomarkers, 221–228
  classification
    diagnostic, 222, 224
    disease activity, 224
    predictive, 221–222
    side effect monitoring, 225
    treatment-response, 225
  clinical end point correlation, 221
  definition, 220
  discovery, 221
  importance, 219–220
  interferon β therapy efficacy monitoring, 248–249
  JC virus antibody, 226
  magnetic resonance imaging, 225–226
  oligoclonal bands, 226
  specificity, 221
  table, 223–224
  validation, 220
Blood–brain barrier (BBB)
  gut microbe short-chain fatty acids and permeability, 147–148
  magnetic resonance imaging of compromise, 55–58
Brain-derived neurotrophic factor (BDNF), glatiramer acetate effects, 267

© 2018 by Cold Spring Harbor Laboratory Press. All rights reserved.

This is a free sample of content from Multiple Sclerosis.
Click here for more information on how to buy the book.

C
CD4+ T cell
activation, 156
experimental autoimmune encephalitis role, 78–79, 170–171
glatiramer acetate modulation, 264
myelin-reactive cells
biomarker utility, 230–231
overview, 158–159
regulatory T-cell mimicry, 188–189
resistance to regulation in multiple sclerosis, 162–164
Th1 cell
gut-associated lymphoid tissue, 142
overview of multiple sclerosis mediation, 1, 159–160
pathology of responses, 161–162
Th17 cell
cytokines in differentiation and plasticity, 171–173
gut-associated lymphoid tissue, 142
interleukin 23
multiple sclerosis mediation, 175–177
programming, 174–175
neuromyelitis optica role, 177–179
overview of multiple sclerosis mediation, 1, 159–160, 169–170
pathology of responses, 160–161
transcription factor networks, 173–174
CD8+ T cell
experimental autoimmune encephalitis role, 79–80
glatiramer acetate modulation, 264
myelin-reactive cells as biomarkers, 230–231
pathology of responses, 162
resistance to regulation in multiple sclerosis, 162–164
CD20, therapeutic targeting, 328–330
CD25, daclizumab effects, 314, 317–319
CD39, 146–147
CDCV. *See* Common disease–common variant
CDMS. *See* Clinically definitive multiple sclerosis
Central vein, magnetic resonance imaging, 61–63
CHI3L1, biomarker utility, 10
CIS. *See* Clinically isolated syndrome
Cladribine
clinical studies, 288, 291
mechanism of action, 288
overview, 287–288
safety, 288–289
Clinically definitive multiple sclerosis (CDMS)
biomarkers, 10
clinical features, 2, 4–5
Clinically isolated syndrome (CIS)
biomarkers, 10
clinical features, 4–5
interferon β clinical trials
BENEFIT, 251–252
CHAMPS, 250–251
ETOMS, 251
overview, 249–250
Coffee, multiple sclerosis risk studies, 36
Common disease–common variant (CDCV), 43–44
CTLA-4, therapeutic targeting, 195
CXCL113, biomarker utility, 10
CXCL13, biomarker utility, 227
CYP27B1, genome-wide association studies, 45

D
Daclizumab
clinical trials, 320–321
mechanism of action, 43, 313–320
prospects for study, 322
safety, 321–322
Diabetes, regulatory T-cell loss of function, 189, 192
Dimethyl fumarate (DMF), experimental autoimmune encephalitis studies of therapy, 84
B-cell effects, 334
clinical studies, 291, 294
hematopoietic stem cell transplantation combination, 346
mechanism of action, 293–294
overview, 293
safety, 294–295
DMF. *See* Dimethyl fumarate

E
EBV. *See* Epstein–Barr virus
ENTPD1, 146
Epstein–Barr virus (EBV), multiple sclerosis risk studies, 30–32
Experimental autoimmune encephalitis (EAE)
antigens as lymphocyte targets, 76
B-cell role, 81–82
CD4+ T-cell role, 78–79, 170–171
CD8+ T-cell role, 79–80
drug development, 83–85
gut microbiota effects, 145–146, 148
microglia studies, 108–111, 114–115
myelin basic protein induction, 76–77
myelin oligodendrocyte glycoprotein induction, 77
proteolipoid protein induction, 77
spontaneous models, 82–83

F
Fingolimod
B-cell effects, 334
clinical studies, 289–291
experimental autoimmune encephalitis studies of therapy, 84
hematopoietic stem cell transplantation combination, 347

© 2018 by Cold Spring Harbor Laboratory Press. All rights reserved.

This is a free sample of content from Multiple Sclerosis.
Click here for more information on how to buy the book.

mechanism of action, 289
microglia effects, 118
overview, 289
safety, 290, 293

G

GA. *See* Glatiramer acetate
Genetic risk score (GRS), disease susceptibility, 46–47
Genome-wide association studies (GWAS)
biomarker discovery, 232
multiple sclerosis, 42–46
GFAP. *See* Glial fibrillary acidic protein
Glatiramer acetate (GA)
B-cell effects, 266–267, 333–334
clinical trials, 267–269
combination therapy, 269
dosing, 269–270
experimental autoimmune encephalitis studies of therapy, 83–84
mechanism of action
adaptive immunity regulation, 262, 264
anti-inflammatory mechanisms, 263–267
neuroprotection, 267
overview, 261–262
pharmacology, 262
prospects for study, 270
safety, 270
Glial fibrillary acidic protein (GFAP), biomarker utility, 229–230
GM-CSF. *See* Granulocyte macrophage colony-stimulating factor
Granulocyte macrophage colony-stimulating factor (GM-CSF)
B-cell production, 210
monoclonal antibody therapy and microglia effects, 119
GRS. *See* Genetic risk score
Gut microbiota
gut-associated lymphoid tissue as reservoir for multiple sclerosis–associated immune cells, 140–142
lipopeptides as biomarkers, 231–232
multiple sclerosis
effects on microbiota, 148–149
regulation mechanisms
blood–brain barrier permeability, 147–148
immunomodulation, 143–147
prospects for study, 139–150

H

HDAC1, 99
Hematopoietic stem cell transplantation (HSCT)
adverse effects
cognitive issues, 352
fatigue, 352
fertility, 353
infection, 352
physical deficit worsening, 352
pseudorelapse triggering, 351
secondary autoimmune disease, 352
sexual dysfunction, 352–353
clinical trials, 342–344
combination therapy sequencing, 346–347
conditioning regimen, 348–350
employment concerns, 353
historical perspective, 341–342
mortality, 347
patient selection, 344–346
prospects, 353–354
stem cell
infusion, engraftment, and recovery, 349
mobilization, 348
timeline, 350
young patients
fertility, 351
financial concerns, 349
roles and responsibilities, 351
Heritability, multiple sclerosis, 41–42
HLA. *See* Human leukocyte antigen
HSCT. *See* Hematopoietic stem cell transplantation
Human leukocyte antigen (HLA)
biomarker utility, 232
susceptibility loci, 30–32, 42, 44, 157

I

IFN-β. *See* Interferon β
IFN-γ. *See* Interferon γ
IL2R
genome-wide association studies, 44
therapeutic targeting, 313–314
IL-6. *See* Interleukin 6
IL7R, genome-wide association studies, 44
IL-10. *See* Interleukin 10
IL-12. *See* Interleukin 12
IL-15. *See* Interleukin 15
IL-23. *See* Interleukin 23
IL-35. *See* Interleukin 35
Inflammation
B cell
antigen presentation, 207–208
meningeal inflammation role, 210–211
glatiramer acetate anti-inflammatory mechanisms, 263–267
imaging, 65
pathology
active lesions, 20
demyelination role, 21–23
neurodegeneration role, 22–23
overview, 15, 19–20
progressive disease, 20–21

© 2018 by Cold Spring Harbor Laboratory Press. All rights reserved.

This is a free sample of content from Multiple Sclerosis.
Click here for more information on how to buy the book.

Interferon β (IFN-β)
microglia effects, 118
therapy
B-cell effects, 333
biomarkers of efficacy, 248–249
clinical trials in relapsing remitting multiple sclerosis
ADVANCE trial, 245–246
dose comparison and outcomes, 246
IFNB Multiple Sclerosis Study Group, 243–244
MSCRG, 244–245
PRISMS trials, 245
clinically isolated syndrome trials
BENEFIT, 251–252
CHAMPS, 250–251
ETOMS, 251
overview, 249–250
comparative studies, 253–254
compliance, 254
experimental autoimmune encephalitis studies, 83
historical perspective, 241
IMPACT trial, 253
mechanism of action, 242–243
observational studies, 246, 248
prospects for study, 254–255
safety, 254
secondary progressive multiple sclerosis trials
EUSPMS, 252–253
NASPMS, 253
overview, 252
SPECTRIMS trial, 253
Interferon γ (IFN-γ), regulatory T-cell secretion, 192–196
Interleukin 6 (IL-6)
B-cell production, 209
Th17 cell differentiation role, 172–173
Interleukin 10 (IL-10), B-cell production, 208
Interleukin 12 (IL-12), Th17 cell differentiation role, 173
Interleukin 15 (IL-15), B-cell production, 209–210
Interleukin 23 (IL-23)
multiple sclerosis mediation, 175–177
Th17 cell programming, 174–175
Interleukin 35 (IL-35), B-cell production, 208

J

JC virus (JCV) antibodies
biomarker utility, 226
progressive multifocal leukoencephalopathy risk mitigation in natalizumab therapy, 280–281
JCV antibodies. *See* JC virus antibodies

K

KIF5A, 99
KIR4.1, antibodies and biomarker utility, 228–229

L

Laquinimod
clinical studies, 292, 296
mechanism of action, 295–296
microglia effects, 119
safety, 296

M

Macrophage. *See* Microglia
Magnetic resonance imaging (MRI)
biomarkers in multiple sclerosis
gray matter atrophy, 225
hyperintense T2-weighted lesions, 225
spinal cord atrophy, 226
whole brain atrophy, 225–226
blood–brain barrier compromise, 55–58
brain atrophy and neurodegeneration, 58–60
central vein, 61–63
cortical lesions, 65–66
disease activity and course determination, 2, 8–9
inflammation, 65
microglia, 112
spinal cord, 60–61
techniques for multiple sclerosis
diffusion tensor imaging, 64–65
magnetization transfer imaging, 63–64
overview, 53–54
T1-weighted spin-echo and gradient-echo imaging, 55–58
T2-weighted spin-echo and inversion-recovery sequences, 54–55
Magnetic resonance spectroscopy (MRS), multiple sclerosis, 63
MBP. *See* Myelin basic protein
Microglia
activation
patterns in lesions, 107–108
rodent versus human, 117
antigen presentation, 113–115
damage response and phagocytosis, 113
experimental autoimmune encephalitis studies, 108–111
imaging biomarker, 111–113
immunomodulation, 116
infection response, 116–117
oligodendrocyte effects, 115–116
overview, 106
oxidative burst and cytotoxicity, 116
phenotypes in acute and chronic lesions, 106–107
senescence, 117
therapeutic targeting, 117–119
MicroRNA (miRNA)
biomarker utility, 227–228
miR-124, microglia effects, 118–119
miRNA. *See* MicroRNA

© 2018 by Cold Spring Harbor Laboratory Press. All rights reserved.

This is a free sample of content from Multiple Sclerosis.
Click here for more information on how to buy the book.

Mitochondria
demyelinated axon changes
complex IV activity, 101–102
energy demands, 100–101
myelinated axon energy demands and mitochondria distribution, 100
neuronal cell bodies
respiratory chain complexes, 96–99
transport machinery, 99–100
therapeutic targeting of respiratory chain complex deficiency, 103
Mitoxantrone
B-cell effects, 334
hematopoietic stem cell transplantation combination, 346–347
MOG. *See* Myelin oligodendrocyte glycoprotein
MPO. *See* Myeloperoxidase
MRI. *See* Magnetic resonance imaging
MRS. *See* Magnetic resonance spectroscopy
Myelin basic protein (MBP)
biomarker utility, 229
experimental autoimmune encephalitis induction, 76–77
Myelin oligodendrocyte glycoprotein (MOG), experimental autoimmune encephalitis induction, 77
Myeloid cell, glatiramer acetate modulation, 265–266
Myeloperoxidase (MPO), biomarker use, 111–112

N

NAA. *See N*-acetylaspartate
N-acetylaspartate (NAA), biomarker utility, 10
Natalizumab
adverse effects
progressive multifocal leukoencephalopathy risks and mitigation, 279–281
side effects, 281–282
antibodies, 282–283
B-cell effects, 334
clinical trials, 278–279
costs, 284
experimental autoimmune encephalitis studies of therapy, 84
hematopoietic stem cell transplantation combination, 347
historical perspective, 277–278
mechanism of action, 276
observational studies, 283
pregnancy studies, 283
reactivation following therapy cessation, 282
Natural killer (NK) cell, daclizumab effects, 316–318, 321–322
Neurofilament, biomarker utility, 10, 229
Neuromyelitis optica (NMO), Th17 cell role, 177–179
NK cell. *See* Natural killer cell
NMO. *See* Neuromyelitis optica
NR1H3, genome-wide association studies, 45

O

Obesity, multiple sclerosis risk studies, 35, 47
Ocrelizumab, B-cell targeting in multiple sclerosis, 329–330
Ofatumumab, B-cell targeting in multiple sclerosis, 330
Oligoclonal bands, biomarker utility, 226
Oligodendrocyte, microglia response, 115–116
OPN. *See* Osteopontin
Osteopontin (OPN), biomarker utility, 230

P

P2Y12, 108
Pathology, multiple sclerosis
active lesions, 16
acute relapsing versus progressive disease, 18–19
gray matter demyelination, 18
inactive lesions, 16
inflammation
active lesions, 20
demyelination role, 21–23
neurodegeneration role, 22–23
overview, 15, 19–20
progressive disease, 20–21
lesion types, 18
overview, 13–16
remyelinated shadow plaques, 16–17
PD-1, therapeutic targeting, 195
PET. *See* Positron emission tomography
PGC-1α, 97
PLP. *See* Proteolipoid protein
PML. *See* Progressive multifocal leukoencephalopathy
Polysaccharide A (PSA), gut microbiota studies, 145–146
Positron emission tomography (PET)
inflammation imaging, 65
microglia, 112–113
PPMS. *See* Primary progressive multiple sclerosis
Primary progressive multiple sclerosis (PPMS)
activity modifiers and progression, 8–9
B-cell targeting in therapy, 330–332
clinical features, 1, 3, 8
PRMS. *See* Progressive relapsing multiple sclerosis
Progressive multifocal leukoencephalopathy (PML), natalizumab risks, 279–281
Progressive relapsing multiple sclerosis (PRMS), 1, 4
Proteolipoid protein (PLP), experimental autoimmune encephalitis induction, 77
PSA. *See* Polysaccharide A

R

Radiologically isolated syndrome (RIS), clinical features, 2, 4

© 2018 by Cold Spring Harbor Laboratory Press. All rights reserved.

This is a free sample of content from Multiple Sclerosis.
Click here for more information on how to buy the book.

Regulatory T cell (Treg)
autoimmune disease end loss of function, 189–193
discovery, 185–186
effector T-cell mimicry for specific immune regulations, 188–189
glatiramer acetate modulation, 264
gut microbiota effects, 144
heterogeneity, 186–187
interferon γ secretion, 192–196
peripheral tolerance role, 187–188
Tr1 cells, 192
Relapsing remitting multiple sclerosis (RRMS)
active lesions, 106
activity modifiers and progression, 8
clinical features, 1, 3, 5–6
interferon β clinical trials
ADVANCE trial, 245–246
dose comparison and outcomes, 246
IFNB Multiple Sclerosis Study Group, 243–244
MSCRG, 244–245
PRISMS trials, 245
Respiratory chain. *See* Mitochondria
RIS. *See* Radiologically isolated syndrome
Rituximab, B-cell targeting in multiple sclerosis, 329
RRMS. *See* Relapsing remitting multiple sclerosis

S

Secondary progressive multiple sclerosis (SPMS)
activity modifiers and progression, 9
clinical features, 1, 3, 6–7
interferon β clinical trials
EUSPMS, 252–253
NASPMS, 253
overview, 252
pathology, 14
SGK-1, 194
Shift work, multiple sclerosis risk studies, 35–36
Smoking. *See* Tobacco
Spinal cord, magnetic resonance imaging, 60–61
SPMS. *See* Secondary progressive multiple sclerosis
Stem cell transplantation. *See* Hematopoietic stem cell transplantation

T

TAGAP, genome-wide association studies, 43
T cell. *See* $CD4^+$ T cell; $CD8^+$ T cell; Regulatory T cell
Teriflunomide
B-cell effects, 334
clinical studies, 292, 297
experimental autoimmune encephalitis studies of therapy, 84
hematopoietic stem cell transplantation combination, 346
mechanism of action, 296–297
overview, 296
safety, 297
TGF-β. *See* Transforming growth factor β
T helper cell. *See* $CD4^+$ T cell
Th1. *See* $CD4^+$ T cell
Th17. *See* $CD4^+$ T cell
TLRs. *See* Toll-like receptors
TMEM119, 107
TNFRSF1A, genome-wide association studies, 44
TOB-1, biomarker utility, 229
Tobacco, multiple sclerosis risk studies, 32–33
Toll-like receptors (TLRs), microglia expression, 110–111, 116
Transforming growth factor β (TGF-β)
B-cell production, 208
Th17 cell differentiation role, 171–172
Treg. *See* Regulatory T cell
TREM2, 108
Tumor necrosis factor, B-cell production, 209

V

Vitamin D, multiple sclerosis risk studies, 33–35, 47
VLA-4, 84, 205

Y

YKL-40, biomarker utility, 227

© 2018 by Cold Spring Harbor Laboratory Press. All rights reserved.